Biotechnology

Shanghai's SinoUnited Health is attracting global patients with advanced care like CAR-T therapy at a fraction of US prices, challenging medical tourism hubs.

With backing from AI leaders, Helical’s virtual lab aims to turn powerful models into reproducible drug discovery systems, tackling a key industry bottleneck.

Win a VIP trip to meet P!NK while supporting vital cancer research. A new fundraising model emerges as public funding for life-saving science dwindles.

Phase 3 data shows GTx-104 reduces key risks and improves outcomes for aSAH patients, positioning it as a potential new standard of care ahead of an FDA decision.

MeiraGTx will present 3-year data on a one-time therapy for radiation-induced dry mouth, a condition affecting millions of head and neck cancer survivors.

Biotech firm Genvor leverages its AI platform in a new partnership, aiming to fast-track novel peptides for anti-aging and weight loss to a booming market.

With its lead depression drug nearing Phase 3, AtaiBeckley faces investors to tackle the regulatory and commercial hurdles of psychedelic medicine.

Eli Lilly acquires CrossBridge Bio for its innovative dual-payload ADC platform, signaling a major push into the next wave of targeted cancer treatments.

BioTesserae's BTC-001, a novel immunotherapy, proves safe in early trials, paving the way for more affordable and accessible treatment for dogs.

As Ontario hospitals face a financial crisis, a major innovation week aims to connect Canadian startups with global capital to solve healthcare's biggest challenges.

Taiwanese biotech GlycoNex will begin human trials for GNX1021, a novel ADC that targets cancer's unique sugar coating to fight GI tumors.

Renaissance Pharma's Daretabart gains FDA support for high-risk neuroblastoma, accelerating its journey to patients and offering new hope against this rare disease.

European non-profit ELRIG launches its first US conference, a free-to-attend event aiming to connect scientists and tackle intractable drug targets.

A landmark grant funds research into scaffold-free tissue, a revolutionary approach that could one day eliminate the need for many knee replacements.

The Jackson Laboratory appoints Steven Holstein to bridge science and capital, supercharging its new integrated platform for developing breakthrough therapies.

French firms Clean Cells and Naobios eye South Korea's booming biopharma sector, offering a rare integrated solution for viral vaccine and therapy development.

A global partnership aims to bring Atla-cel, a next-gen CAR-T therapy with low neurotoxicity, to children with leukaemia, potentially revolutionizing treatment.

A new once-daily pill for hypoparathyroidism begins human testing, promising to replace burdensome injections and transform patient care. Is this the future?

With new funding, ImageneBio advances its unique OX40 inhibitor, IMG-007, for eczema and alopecia, but faces a divided Wall Street.

Orum Therapeutics adds deep clinical and dealmaking expertise to its board, signaling a strategic acceleration of its innovative DAC pipeline for cancer.